http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2024, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 30 Oct 2024 06:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html <div class="xn-content"> <p><i>--</i><i> Oversubscribed financing brings together leading syndicate of life sciences investors --</i></p> <p><i>-- Proceeds to support clinical development of first-in-class therapies for neurological disorders –</i></p> <p><span class="legendSpanClass"><location value="LU/us.ma.boston" idsrc="xmltag.org" >BOSTON</location></span>, <span class="legendSpanClass"><chron>Oct. 30, 2024</chron></span> /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed <money>$115 million</money> Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essential for http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html Wed, 30 Oct 2024 06:00:00 -0400 A.10057105 A.19655944 A.24866445 A.35954321 A.37612190 A.40702768 A.50114227 A.50201820 AKRO APLS AUPH BMS CINC CMPI HRMY O.00888987 O.03307993 O.20314535 O.20737027 O.21811137 O.25604838 O.29407519 O.40918370 O.41106600 O.41321359 O.47912200 O.48199818 PHVS RYZB TPTX http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html <div class="xn-content"> <p><i>--</i><i> Oversubscribed financing brings together leading syndicate of life sciences investors --</i></p> <p><i>-- Proceeds to support clinical development of first-in-class therapies for neurological disorders –</i></p> <p><span class="legendSpanClass"><location value="LU/us.ma.boston" idsrc="xmltag.org" >BOSTON</location></span>, <span class="legendSpanClass"><chron>Oct. 30, 2024</chron></span> /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed <money>$115 million</money> Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essential for http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html Wed, 30 Oct 2024 06:00:00 -0400 A.10057105 A.19655944 A.24866445 A.35954321 A.37612190 A.40702768 A.50114227 A.50201820 AKRO APLS AUPH BMS CINC CMPI HRMY O.00888987 O.03307993 O.20314535 O.20737027 O.21811137 O.25604838 O.29407519 O.40918370 O.41106600 O.41321359 O.47912200 O.48199818 PHVS RYZB TPTX http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html <div class="xn-content"> <p><i>--</i><i> Oversubscribed financing brings together leading syndicate of life sciences investors --</i></p> <p><i>-- Proceeds to support clinical development of first-in-class therapies for neurological disorders –</i></p> <p><span class="legendSpanClass"><location value="LU/us.ma.boston" idsrc="xmltag.org" >BOSTON</location></span>, <span class="legendSpanClass"><chron>Oct. 30, 2024</chron></span> /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed <money>$115 million</money> Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essential for http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html Wed, 30 Oct 2024 06:00:00 -0400 A.10057105 A.19655944 A.24866445 A.35954321 A.37612190 A.40702768 A.50114227 A.50201820 AKRO APLS AUPH BMS CINC CMPI HRMY O.00888987 O.03307993 O.20314535 O.20737027 O.21811137 O.25604838 O.29407519 O.40918370 O.41106600 O.41321359 O.47912200 O.48199818 PHVS RYZB TPTX http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html <div class="xn-content"> <p><i>--</i><i> Oversubscribed financing brings together leading syndicate of life sciences investors --</i></p> <p><i>-- Proceeds to support clinical development of first-in-class therapies for neurological disorders –</i></p> <p><span class="legendSpanClass"><location value="LU/us.ma.boston" idsrc="xmltag.org" >BOSTON</location></span>, <span class="legendSpanClass"><chron>Oct. 30, 2024</chron></span> /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed <money>$115 million</money> Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essential for http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html Wed, 30 Oct 2024 06:00:00 -0400 A.10057105 A.19655944 A.24866445 A.35954321 A.37612190 A.40702768 A.50114227 A.50201820 AKRO APLS AUPH BMS CINC CMPI HRMY O.00888987 O.03307993 O.20314535 O.20737027 O.21811137 O.25604838 O.29407519 O.40918370 O.41106600 O.41321359 O.47912200 O.48199818 PHVS RYZB TPTX http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html <div class="xn-content"> <p><i>--</i><i> Oversubscribed financing brings together leading syndicate of life sciences investors --</i></p> <p><i>-- Proceeds to support clinical development of first-in-class therapies for neurological disorders –</i></p> <p><span class="legendSpanClass"><location value="LU/us.ma.boston" idsrc="xmltag.org" >BOSTON</location></span>, <span class="legendSpanClass"><chron>Oct. 30, 2024</chron></span> /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed <money>$115 million</money> Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essential for http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html Wed, 30 Oct 2024 06:00:00 -0400 A.10057105 A.19655944 A.24866445 A.35954321 A.37612190 A.40702768 A.50114227 A.50201820 AKRO APLS AUPH BMS CINC CMPI HRMY O.00888987 O.03307993 O.20314535 O.20737027 O.21811137 O.25604838 O.29407519 O.40918370 O.41106600 O.41321359 O.47912200 O.48199818 PHVS RYZB TPTX http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html <div class="xn-content"> <p><i>--</i><i> Oversubscribed financing brings together leading syndicate of life sciences investors --</i></p> <p><i>-- Proceeds to support clinical development of first-in-class therapies for neurological disorders –</i></p> <p><span class="legendSpanClass"><location value="LU/us.ma.boston" idsrc="xmltag.org" >BOSTON</location></span>, <span class="legendSpanClass"><chron>Oct. 30, 2024</chron></span> /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed <money>$115 million</money> Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essential for http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html Wed, 30 Oct 2024 06:00:00 -0400 A.10057105 A.19655944 A.24866445 A.35954321 A.37612190 A.40702768 A.50114227 A.50201820 AKRO APLS AUPH BMS CINC CMPI HRMY O.00888987 O.03307993 O.20314535 O.20737027 O.21811137 O.25604838 O.29407519 O.40918370 O.41106600 O.41321359 O.47912200 O.48199818 PHVS RYZB TPTX http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html <div class="xn-content"> <p><i>--</i><i> Oversubscribed financing brings together leading syndicate of life sciences investors --</i></p> <p><i>-- Proceeds to support clinical development of first-in-class therapies for neurological disorders –</i></p> <p><span class="legendSpanClass"><location value="LU/us.ma.boston" idsrc="xmltag.org" >BOSTON</location></span>, <span class="legendSpanClass"><chron>Oct. 30, 2024</chron></span> /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed <money>$115 million</money> Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essential for http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html Wed, 30 Oct 2024 06:00:00 -0400 A.10057105 A.19655944 A.24866445 A.35954321 A.37612190 A.40702768 A.50114227 A.50201820 AKRO APLS AUPH BMS CINC CMPI HRMY O.00888987 O.03307993 O.20314535 O.20737027 O.21811137 O.25604838 O.29407519 O.40918370 O.41106600 O.41321359 O.47912200 O.48199818 PHVS RYZB TPTX http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html <div class="xn-content"> <p><i>--</i><i> Oversubscribed financing brings together leading syndicate of life sciences investors --</i></p> <p><i>-- Proceeds to support clinical development of first-in-class therapies for neurological disorders –</i></p> <p><span class="legendSpanClass"><location value="LU/us.ma.boston" idsrc="xmltag.org" >BOSTON</location></span>, <span class="legendSpanClass"><chron>Oct. 30, 2024</chron></span> /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed <money>$115 million</money> Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essential for http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html Wed, 30 Oct 2024 06:00:00 -0400 A.10057105 A.19655944 A.24866445 A.35954321 A.37612190 A.40702768 A.50114227 A.50201820 AKRO APLS AUPH BMS CINC CMPI HRMY O.00888987 O.03307993 O.20314535 O.20737027 O.21811137 O.25604838 O.29407519 O.40918370 O.41106600 O.41321359 O.47912200 O.48199818 PHVS RYZB TPTX http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html <div class="xn-content"> <p><i>--</i><i> Oversubscribed financing brings together leading syndicate of life sciences investors --</i></p> <p><i>-- Proceeds to support clinical development of first-in-class therapies for neurological disorders –</i></p> <p><span class="legendSpanClass"><location value="LU/us.ma.boston" idsrc="xmltag.org" >BOSTON</location></span>, <span class="legendSpanClass"><chron>Oct. 30, 2024</chron></span> /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed <money>$115 million</money> Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essential for http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html Wed, 30 Oct 2024 06:00:00 -0400 A.10057105 A.19655944 A.24866445 A.35954321 A.37612190 A.40702768 A.50114227 A.50201820 AKRO APLS AUPH BMS CINC CMPI HRMY O.00888987 O.03307993 O.20314535 O.20737027 O.21811137 O.25604838 O.29407519 O.40918370 O.41106600 O.41321359 O.47912200 O.48199818 PHVS RYZB TPTX http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html <div class="xn-content"> <p><i>--</i><i> Oversubscribed financing brings together leading syndicate of life sciences investors --</i></p> <p><i>-- Proceeds to support clinical development of first-in-class therapies for neurological disorders –</i></p> <p><span class="legendSpanClass"><location value="LU/us.ma.boston" idsrc="xmltag.org" >BOSTON</location></span>, <span class="legendSpanClass"><chron>Oct. 30, 2024</chron></span> /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed <money>$115 million</money> Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essential for http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html Wed, 30 Oct 2024 06:00:00 -0400 A.10057105 A.19655944 A.24866445 A.35954321 A.37612190 A.40702768 A.50114227 A.50201820 AKRO APLS AUPH BMS CINC CMPI HRMY O.00888987 O.03307993 O.20314535 O.20737027 O.21811137 O.25604838 O.29407519 O.40918370 O.41106600 O.41321359 O.47912200 O.48199818 PHVS RYZB TPTX http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html <div class="xn-content"> <p><i>--</i><i> Oversubscribed financing brings together leading syndicate of life sciences investors --</i></p> <p><i>-- Proceeds to support clinical development of first-in-class therapies for neurological disorders –</i></p> <p><span class="legendSpanClass"><location value="LU/us.ma.boston" idsrc="xmltag.org" >BOSTON</location></span>, <span class="legendSpanClass"><chron>Oct. 30, 2024</chron></span> /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed <money>$115 million</money> Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essential for http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html Wed, 30 Oct 2024 06:00:00 -0400 A.10057105 A.19655944 A.24866445 A.35954321 A.37612190 A.40702768 A.50114227 A.50201820 AKRO APLS AUPH BMS CINC CMPI HRMY O.00888987 O.03307993 O.20314535 O.20737027 O.21811137 O.25604838 O.29407519 O.40918370 O.41106600 O.41321359 O.47912200 O.48199818 PHVS RYZB TPTX http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html <div class="xn-content"> <p><i>--</i><i> Oversubscribed financing brings together leading syndicate of life sciences investors --</i></p> <p><i>-- Proceeds to support clinical development of first-in-class therapies for neurological disorders –</i></p> <p><span class="legendSpanClass"><location value="LU/us.ma.boston" idsrc="xmltag.org" >BOSTON</location></span>, <span class="legendSpanClass"><chron>Oct. 30, 2024</chron></span> /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed <money>$115 million</money> Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essential for http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html Wed, 30 Oct 2024 06:00:00 -0400 A.10057105 A.19655944 A.24866445 A.35954321 A.37612190 A.40702768 A.50114227 A.50201820 AKRO APLS AUPH BMS CINC CMPI HRMY O.00888987 O.03307993 O.20314535 O.20737027 O.21811137 O.25604838 O.29407519 O.40918370 O.41106600 O.41321359 O.47912200 O.48199818 PHVS RYZB TPTX http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html <div class="xn-content"> <p><i>--</i><i> Oversubscribed financing brings together leading syndicate of life sciences investors --</i></p> <p><i>-- Proceeds to support clinical development of first-in-class therapies for neurological disorders –</i></p> <p><span class="legendSpanClass"><location value="LU/us.ma.boston" idsrc="xmltag.org" >BOSTON</location></span>, <span class="legendSpanClass"><chron>Oct. 30, 2024</chron></span> /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed <money>$115 million</money> Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essential for http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html Wed, 30 Oct 2024 06:00:00 -0400 A.10057105 A.19655944 A.24866445 A.35954321 A.37612190 A.40702768 A.50114227 A.50201820 AKRO APLS AUPH BMS CINC CMPI HRMY O.00888987 O.03307993 O.20314535 O.20737027 O.21811137 O.25604838 O.29407519 O.40918370 O.41106600 O.41321359 O.47912200 O.48199818 PHVS RYZB TPTX http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html <div class="xn-content"> <p><i>--</i><i> Oversubscribed financing brings together leading syndicate of life sciences investors --</i></p> <p><i>-- Proceeds to support clinical development of first-in-class therapies for neurological disorders –</i></p> <p><span class="legendSpanClass"><location value="LU/us.ma.boston" idsrc="xmltag.org" >BOSTON</location></span>, <span class="legendSpanClass"><chron>Oct. 30, 2024</chron></span> /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed <money>$115 million</money> Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essential for http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html Wed, 30 Oct 2024 06:00:00 -0400 A.10057105 A.19655944 A.24866445 A.35954321 A.37612190 A.40702768 A.50114227 A.50201820 AKRO APLS AUPH BMS CINC CMPI HRMY O.00888987 O.03307993 O.20314535 O.20737027 O.21811137 O.25604838 O.29407519 O.40918370 O.41106600 O.41321359 O.47912200 O.48199818 PHVS RYZB TPTX http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html <div class="xn-content"> <p><i>--</i><i> Oversubscribed financing brings together leading syndicate of life sciences investors --</i></p> <p><i>-- Proceeds to support clinical development of first-in-class therapies for neurological disorders –</i></p> <p><span class="legendSpanClass"><location value="LU/us.ma.boston" idsrc="xmltag.org" >BOSTON</location></span>, <span class="legendSpanClass"><chron>Oct. 30, 2024</chron></span> /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed <money>$115 million</money> Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essential for http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html Wed, 30 Oct 2024 06:00:00 -0400 A.10057105 A.19655944 A.24866445 A.35954321 A.37612190 A.40702768 A.50114227 A.50201820 AKRO APLS AUPH BMS CINC CMPI HRMY O.00888987 O.03307993 O.20314535 O.20737027 O.21811137 O.25604838 O.29407519 O.40918370 O.41106600 O.41321359 O.47912200 O.48199818 PHVS RYZB TPTX http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html <div class="xn-content"> <p><i>--</i><i> Oversubscribed financing brings together leading syndicate of life sciences investors --</i></p> <p><i>-- Proceeds to support clinical development of first-in-class therapies for neurological disorders –</i></p> <p><span class="legendSpanClass"><location value="LU/us.ma.boston" idsrc="xmltag.org" >BOSTON</location></span>, <span class="legendSpanClass"><chron>Oct. 30, 2024</chron></span> /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed <money>$115 million</money> Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essential for http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html Wed, 30 Oct 2024 06:00:00 -0400 A.10057105 A.19655944 A.24866445 A.35954321 A.37612190 A.40702768 A.50114227 A.50201820 AKRO APLS AUPH BMS CINC CMPI HRMY O.00888987 O.03307993 O.20314535 O.20737027 O.21811137 O.25604838 O.29407519 O.40918370 O.41106600 O.41321359 O.47912200 O.48199818 PHVS RYZB TPTX http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html <div class="xn-content"> <p><i>--</i><i> Oversubscribed financing brings together leading syndicate of life sciences investors --</i></p> <p><i>-- Proceeds to support clinical development of first-in-class therapies for neurological disorders –</i></p> <p><span class="legendSpanClass"><location value="LU/us.ma.boston" idsrc="xmltag.org" >BOSTON</location></span>, <span class="legendSpanClass"><chron>Oct. 30, 2024</chron></span> /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed <money>$115 million</money> Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essential for http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html Wed, 30 Oct 2024 06:00:00 -0400 A.10057105 A.19655944 A.24866445 A.35954321 A.37612190 A.40702768 A.50114227 A.50201820 AKRO APLS AUPH BMS CINC CMPI HRMY O.00888987 O.03307993 O.20314535 O.20737027 O.21811137 O.25604838 O.29407519 O.40918370 O.41106600 O.41321359 O.47912200 O.48199818 PHVS RYZB TPTX http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html <div class="xn-content"> <p><i>--</i><i> Oversubscribed financing brings together leading syndicate of life sciences investors --</i></p> <p><i>-- Proceeds to support clinical development of first-in-class therapies for neurological disorders –</i></p> <p><span class="legendSpanClass"><location value="LU/us.ma.boston" idsrc="xmltag.org" >BOSTON</location></span>, <span class="legendSpanClass"><chron>Oct. 30, 2024</chron></span> /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed <money>$115 million</money> Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essential for http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html Wed, 30 Oct 2024 06:00:00 -0400 A.10057105 A.19655944 A.24866445 A.35954321 A.37612190 A.40702768 A.50114227 A.50201820 AKRO APLS AUPH BMS CINC CMPI HRMY O.00888987 O.03307993 O.20314535 O.20737027 O.21811137 O.25604838 O.29407519 O.40918370 O.41106600 O.41321359 O.47912200 O.48199818 PHVS RYZB TPTX http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html <div class="xn-content"> <p><i>--</i><i> Oversubscribed financing brings together leading syndicate of life sciences investors --</i></p> <p><i>-- Proceeds to support clinical development of first-in-class therapies for neurological disorders –</i></p> <p><span class="legendSpanClass"><location value="LU/us.ma.boston" idsrc="xmltag.org" >BOSTON</location></span>, <span class="legendSpanClass"><chron>Oct. 30, 2024</chron></span> /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed <money>$115 million</money> Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essential for http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html Wed, 30 Oct 2024 06:00:00 -0400 A.10057105 A.19655944 A.24866445 A.35954321 A.37612190 A.40702768 A.50114227 A.50201820 AKRO APLS AUPH BMS CINC CMPI HRMY O.00888987 O.03307993 O.20314535 O.20737027 O.21811137 O.25604838 O.29407519 O.40918370 O.41106600 O.41321359 O.47912200 O.48199818 PHVS RYZB TPTX http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html <div class="xn-content"> <p><i>--</i><i> Oversubscribed financing brings together leading syndicate of life sciences investors --</i></p> <p><i>-- Proceeds to support clinical development of first-in-class therapies for neurological disorders –</i></p> <p><span class="legendSpanClass"><location value="LU/us.ma.boston" idsrc="xmltag.org" >BOSTON</location></span>, <span class="legendSpanClass"><chron>Oct. 30, 2024</chron></span> /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed <money>$115 million</money> Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essential for http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html Wed, 30 Oct 2024 06:00:00 -0400 A.10057105 A.19655944 A.24866445 A.35954321 A.37612190 A.40702768 A.50114227 A.50201820 AKRO APLS AUPH BMS CINC CMPI HRMY O.00888987 O.03307993 O.20314535 O.20737027 O.21811137 O.25604838 O.29407519 O.40918370 O.41106600 O.41321359 O.47912200 O.48199818 PHVS RYZB TPTX http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html <div class="xn-content"> <p><i>--</i><i> Oversubscribed financing brings together leading syndicate of life sciences investors --</i></p> <p><i>-- Proceeds to support clinical development of first-in-class therapies for neurological disorders –</i></p> <p><span class="legendSpanClass"><location value="LU/us.ma.boston" idsrc="xmltag.org" >BOSTON</location></span>, <span class="legendSpanClass"><chron>Oct. 30, 2024</chron></span> /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed <money>$115 million</money> Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essential for http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html Wed, 30 Oct 2024 06:00:00 -0400 A.10057105 A.19655944 A.24866445 A.35954321 A.37612190 A.40702768 A.50114227 A.50201820 AKRO APLS AUPH BMS CINC CMPI HRMY O.00888987 O.03307993 O.20314535 O.20737027 O.21811137 O.25604838 O.29407519 O.40918370 O.41106600 O.41321359 O.47912200 O.48199818 PHVS RYZB TPTX http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html <div class="xn-content"> <p><i>--</i><i> Oversubscribed financing brings together leading syndicate of life sciences investors --</i></p> <p><i>-- Proceeds to support clinical development of first-in-class therapies for neurological disorders –</i></p> <p><span class="legendSpanClass"><location value="LU/us.ma.boston" idsrc="xmltag.org" >BOSTON</location></span>, <span class="legendSpanClass"><chron>Oct. 30, 2024</chron></span> /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed <money>$115 million</money> Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essential for http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html Wed, 30 Oct 2024 06:00:00 -0400 A.10057105 A.19655944 A.24866445 A.35954321 A.37612190 A.40702768 A.50114227 A.50201820 AKRO APLS AUPH BMS CINC CMPI HRMY O.00888987 O.03307993 O.20314535 O.20737027 O.21811137 O.25604838 O.29407519 O.40918370 O.41106600 O.41321359 O.47912200 O.48199818 PHVS RYZB TPTX http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html <div class="xn-content"> <p><i>--</i><i> Oversubscribed financing brings together leading syndicate of life sciences investors --</i></p> <p><i>-- Proceeds to support clinical development of first-in-class therapies for neurological disorders –</i></p> <p><span class="legendSpanClass"><location value="LU/us.ma.boston" idsrc="xmltag.org" >BOSTON</location></span>, <span class="legendSpanClass"><chron>Oct. 30, 2024</chron></span> /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed <money>$115 million</money> Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essential for http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html Wed, 30 Oct 2024 06:00:00 -0400 A.10057105 A.19655944 A.24866445 A.35954321 A.37612190 A.40702768 A.50114227 A.50201820 AKRO APLS AUPH BMS CINC CMPI HRMY O.00888987 O.03307993 O.20314535 O.20737027 O.21811137 O.25604838 O.29407519 O.40918370 O.41106600 O.41321359 O.47912200 O.48199818 PHVS RYZB TPTX http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html <div class="xn-content"> <p><i>--</i><i> Oversubscribed financing brings together leading syndicate of life sciences investors --</i></p> <p><i>-- Proceeds to support clinical development of first-in-class therapies for neurological disorders –</i></p> <p><span class="legendSpanClass"><location value="LU/us.ma.boston" idsrc="xmltag.org" >BOSTON</location></span>, <span class="legendSpanClass"><chron>Oct. 30, 2024</chron></span> /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed <money>$115 million</money> Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essential for http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html Wed, 30 Oct 2024 06:00:00 -0400 A.10057105 A.19655944 A.24866445 A.35954321 A.37612190 A.40702768 A.50114227 A.50201820 AKRO APLS AUPH BMS CINC CMPI HRMY O.00888987 O.03307993 O.20314535 O.20737027 O.21811137 O.25604838 O.29407519 O.40918370 O.41106600 O.41321359 O.47912200 O.48199818 PHVS RYZB TPTX http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html <div class="xn-content"> <p><i>--</i><i> Oversubscribed financing brings together leading syndicate of life sciences investors --</i></p> <p><i>-- Proceeds to support clinical development of first-in-class therapies for neurological disorders –</i></p> <p><span class="legendSpanClass"><location value="LU/us.ma.boston" idsrc="xmltag.org" >BOSTON</location></span>, <span class="legendSpanClass"><chron>Oct. 30, 2024</chron></span> /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed <money>$115 million</money> Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essential for http://www.streetinsider.com/Press+Releases/Axonis+Therapeutics+Announces+%24115+Million+Series+A+Financing/23897359.html Wed, 30 Oct 2024 06:00:00 -0400 A.10057105 A.19655944 A.24866445 A.35954321 A.37612190 A.40702768 A.50114227 A.50201820 AKRO APLS AUPH BMS CINC CMPI HRMY O.00888987 O.03307993 O.20314535 O.20737027 O.21811137 O.25604838 O.29407519 O.40918370 O.41106600 O.41321359 O.47912200 O.48199818 PHVS RYZB TPTX